Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in Gram-negative sepsis

FASEB Journal

Volumn 20, Issue 12, 2006, Pages

  Berbée, Jimmy F P ^a,b   Van Der Hoogt, Caroline C ^a,b   Kleemann, Robert ^a,b   Schippers, Emile F ^b   Kitchens, Richard L ^c   Van Dissel, Jaap T ^b   Bakker Woudenberg, Irma A J M ^d   Havekes, Louis M ^a,b   Rensen, Patrick C N ^a,b  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Inflammation; Lipoprotein; Macrophage; TNF ; Transgenic mice

Indexed keywords

APOLIPOPROTEIN C1; HIGH DENSITY LIPOPROTEIN; LIPOPOLYSACCHARIDE; APOLIPOPROTEIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GRAM NEGATIVE SEPSIS; IN VITRO STUDY; INFLAMMATION; KLEBSIELLA PNEUMONIAE; MALE; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BINDING; ANIMAL; ANTIGEN PRESENTATION; BINDING SITE; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNITY; IMMUNOLOGY; MACROPHAGE; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; SEPSIS; TRANSGENIC MOUSE;

KLEBSIELLA PNEUMONIAE; MUS MUSCULUS; NEGIBACTERIA;

ANIMALS; ANTIGEN PRESENTATION; APOLIPOPROTEIN C-I; APOLIPOPROTEINS C; BINDING SITES; CONSERVED SEQUENCE; GRAM-NEGATIVE BACTERIA; HUMANS; IMMUNITY; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SEPSIS;

EID: 33845611009     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.05-5639fje     Document Type: Article

References (56)

1. Martin, G. S., Mannino, D. M., Eaton, S., and Moss, M. (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554
2. Riedemann, N. C., Guo, R. F., and Ward, P. A. (2003) Novel strategies for the treatment of sepsis. Nat Med. 9, 517-524
3. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., et al. (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282, 2085-2088
4. Hagberg, L., Hull, R., Hull, S., McGhee, J. R., Michalek, S. M., and Svanborg Eden, C. (1984) Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect. Immun. 46, 839-844
5. Branger, J., Knapp, S., Weijer, S., Leemans, J. C., Pater, J. M., Speelman, P., Florquin, S., and van der Poll, T. (2004) Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice. Infect. Immun. 72, 788-794
6. Schurr, J. R., Young, E., Byrne, P., Steele, C., Shellito, J. E., and Kolls, J. K. (2005) Central role of toll-like receptor 4 signaling and host defense in experimental pneumonia caused by Gram-negative bacteria. Infect. Immun. 73, 532-545
7. Wang, X., Moser, C., Louboutin, J. P., Lysenko, E. S., Weiner, D. J., Weiser, J. N., and Wilson, J. M. (2002) Toll-like receptor 4 mediates innate immune responses to Haemophilus influenzae infection in mouse lung. J. Immunol. 168, 810-815
8. Wang, M., Jeng, K. C., and Ping, L. I. (1999) Exogenous cytokine modulation or neutralization of interleukin-10 enhance survival in lipopolysaccharide-hyporesponsive C3H/HeJ mice with Klebsiella infection. Immunology 98, 90-97
9. Woods, J. P., Frelinger, J. A., Warrack, G., and Cannon, J. G. (1988) Mouse genetic locus Lps influences susceptibility to Neisseria meningitidis infection. Infect. Immun. 56, 1950-1955
10. Bernheiden, M., Heinrich, J. M., Minigo, G., Schutt, C., Stelter, F., Freeman, M., Golenbock, D., and Jack, R. S. (2001) LBP, CD14, TLR4 and the murine innate immune response to a peritoneal Salmonella infection. J. Endotoxin Res. 7, 447-450
11. Echtenacher, B., Falk, W., Mannel, D. N., and Krammer, P. H. (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145, 3762-3766
12. Bagby, G. J., Plessala, K. J., Wilson, L. A., Thompson, J. J., and Nelson, S. (1991) Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. J. Infect. Dis. 163, 83-88
13. Alexander, H. R., Sheppard, B. C., Jensen, J. C., Langstein, H. N., Buresh, C. M., Venzon, D., Walker, E. C., Fraker, D. L., Stovroff, M. C., and Norton, J. A. (1991) Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J. Clin. Invest. 88, 34-39
14. Mastroeni, P., Arena, A., Costa, G. B., Liberto, M. C., Bonina, L., and Hormaeche, C. E. (1991) Serum TNFalpha in mouse typhoid and enhancement of a Salmonella infection by anti-TNFalpha antibodies. Microb. Pathog. 11, 33-38
15. Rothe, J., Lesslauer, W., Lotscher, H., Lang, Y., Koebel, P., Kontgen, F., Althage, A., Zinkernagel, R., Steinmetz, M., and Bluethmann, H. (1993) Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364, 798-802
16. Van Furth, R., van Zwet, T. L., Buisman, A. M., and van Dissel, J. T. (1994) Anti-tumor necrosis factor antibodies inhibit the influx of granulocytes and monocytes into an inflammatory exudate and enhance the growth of Listeria monocytogenes in various organs. J. Infect. Dis. 170, 234-237
17. Van der Poll, T., Keogh, C. V., Buurman, W. A., and Lowry, S. F. (1997) Passive immunization against tumor necrosis factor-alpha impairs host defense during pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 155, 603-608
18. Nara, C., Tateda, K., Matsumoto, T., Ohara, A., Miyazaki, S., Standiford, T. J., and Yamaguchi, K. (2004) Legionella-induced acute lung injury in the setting of hyperoxia: protective role of tumour necrosis factor-alpha. J. Med. Microbiol. 53, 727-733
19. Moore, T. A., Lau, H. Y., Cogen, A. L., Monteleon, C. L., and Standiford, T. J. (2003) Anti-tumor necrosis factor-alpha therapy during murine Klebsiella pneumoniae bacteremia: increased mortality in the absence of liver injury. Shock 20, 309-315
20. Eichacker, P. Q., Parent, C., Kalil, A., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., and Natanson, C. (2002) Risk and the efficacy of anti-inflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197-1205
21. Westendorp, R. G., Langermans, J. A., de Bel, C. E., Meinders, A. E., Vandenbroucke, J. P., van Furth, R., and van Dissel, J. T. (1995) Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J. Infect. Dis. 171, 1057-1060
22. Westendorp, R. G., Langermans, J. A., Huizinga, T. W., Elouali, A. H., Verweij, C. L., Boomsma, D. I., Vandenbroucke, J. P., and Vandenbrouke, J. P. (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349, 170-173
23. Van Dissel, J. T., van Langevelde, P., Westendorp, R. G., Kwappenberg, K., and Frolich, M. (1998) Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351, 950-953
24. Netea, M. G., van der Meer, J. W., van Deuren, M., and Kullberg, B. J. (2003) Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol. 24, 254-258
25. Harris, H. W., Gosnell, J. E., and Kumwenda, Z. L. (2000) The lipemia of sepsis: triglyceride-rich lipoproteins as agents of innate immunity. J. Endotoxin Res. 6, 421-430
26. Flegel, W. A., Baumstark, M. W., Weinstock, C., Berg, A., and Northoff, H. (1993) Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect. Immun. 61, 5140-5146
27. Harris, H. W., Grunfeld, C., Feingold, K. R., and Rapp, J. H. (1990) Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice. J. Clin. Invest. 86, 696-702
28. Rensen, P. C., Oosten, M., Bilt, E., Eck, M., Kuiper, J., and Berkel, T. J. (1997) Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo. J. Clin. Invest. 99, 2438-2445
29. Van Oosten, M., Rensen, P. C., Van Amersfoort, E. S., Van Eck, M., Van Dam, A. M., Breve, J. J., Vogel, T., Panet, A., Van Berkel, T. J., and Kuiper, J. (2001) Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J. Biol. Chem. 276, 8820-8824
30. Mahley, R. W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630
31. Berbee, J. F., van der Hoogt, C. C., Sundararaman, D., Havekes, L. M., and Rensen, P. C. (2005) Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J. Lipid Res. 46, 297-306
32. Jong, M. C., Dahlmans, V. E., van Gorp, P. J., van Dijk, K. W., Breuer, M. L., Hofker, M. H., and Havekes, L. M. (1996) In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J. Clin. Invest. 98, 2259-2267
33. Barlage, S., Frohlich, D., Bottcher, A., Jauhiainen, M., Muller, H. P., Noetzel, F., Rothe, G., Schutt, C., Linke, R. P., Lackner, K. J., et al. (2001) ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J. Lipid Res. 42, 281-290
34. Van Ree, J. H., Hofker, M. H., van den Broek, W. J., van Deursen, J. M., van der Boom, H., Frants, R. R., Wieringa, B., and Havekes, L. M. (1995) Increased response to cholesterol feeding in apolipoprotein C1-deficient mice. Biochem. J. 305, 905-911
35. Troelstra, A., Antal-Szalmas, P., de Graaf-Miltenburg, L. A., Weersink, A. J., Verhoef, J., Van Kessel, K. P., and Van Strijp, J. A. (1997) Saturable CD14-dependent binding of fluorescein-labeled lipopolysaccharide to human monocytes. Infect. Immun. 65, 2272-2277
36. Rensen, P. C., Herijgers, N., Netscher, M. H., Meskers, S. C., van Eck, M., and van Berkel, T. J. (1997) Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38, 1070-1084
37. Kleemann, R., Gervois, P. P., Verschuren, L., Staels, B., Princen, H. M., and Kooistra, T. (2003) Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101, 545-551
38. De Haas, C. J., van der Zee, R., Benaissa-Trouw, B., van Kessel, K. P., Verhoef, J., and van Strijp, J. A. (1999) Lipopolysaccharide (LPS)-binding synthetic peptides derived from serum amyloid P component neutralize LPS. Infect. Immun. 67, 2790-2796
39. Hoess, A., Watson, S., Siber, G. R., and Liddington, R. (1993) Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution. EMBO J. 12, 3351-3356
40. Larrick, J. W., Hirata, M., Zheng, H., Zhong, J., Bolin, D., Cavaillon, J. M., Warren, H. S., and Wright, S. C. (1994) A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J. Immunol. 152, 231-240
41. Weinberg, R. B. (1994) Identification of functional domains in the plasma apolipoproteins by analysis of inter-species sequence variability. J. Lipid Res. 35, 2212-2222
42. Espirito Santo, S. M., Rensen, P. C., Goudriaan, J. R., Bensadoun, A., Bovenschen, N., Voshol, P. J., Havekes, L. M., and van Vlijmen, B. J. (2005) Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. J. Lipid Res. 46, 1097-1102
43. Bakker-Woudenberg, I. A. (2003) Experimental models of pulmonary infection. J. Microbiol. Methods 54, 295-313
44. Shachter, N. S., Ebara, T., Ramakrishnan, R., Steiner, G., Breslow, J. L., Ginsberg, H. N., and Smith, J. D. (1996) Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein C1. J. Clin. Invest. 98, 846-855
45. Echtenacher, B., Freudenberg, M. A., Jack, R. S., and Mannel, D. N. (2001) Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis. Infect. Immun. 69, 7271-7276
46. Deitch, E. A. (1998) Animal models of sepsis and shock: a review and lessons learned. Shock 9, 1-11
47. Cross, A. S., Opal, S. M., Sadoff, J. C., and Gemski, P. (1993) Choice of bacteria in animal models of sepsis. Infect. Immun. 61, 2741-2747
48. Rehm, S. R., Gross, G. N., and Pierce, A. K. (1980) Early bacterial clearance from murine lungs. Species-dependent phagocyte response. J. Clin. Invest. 66, 194-199
49. De Bont, N., Netea, M. G., Demacker, P. N., Kullberg, B. J., van der Meer, J. W., and Stalenhoef, A. F. (2000) Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur J. Clin. Invest. 30, 818-822
50. Calandra, T., Echtenacher, B., Roy, D. L., Pugin, J., Metz, C. N., Hultner, L., Heumann, D., Mannel, D., Bucala, R., and Glauser, M. P. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6, 164-170
51. Calandra, T., and Roger, T. (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3, 791-800
52. Akira, S., and Takeda, K. (2004) Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511
53. Beutler, B. (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257-263
54. Mullarkey, M., Rose, J. R., Bristol, J., Kawata, T., Kimura, A., Kobayashi, S., Przetak, M., Chow, J., Gusovsky, F., Christ, W. J., et al. (2003) Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304, 1093-1102
55. Solomon, S. B., Cui, X., Gerstenberger, E., Danner, R. L., Fitz, Y., Banks, S. M., Natanson, C., and Eichacker, P. Q. (2006) Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J. Infect. Dis. 193, 634-644
56. Cohn, J. S., Tremblay, M., Boulet, L., Jacques, H., Davignon, J., Roy, M., and Bernier, L. (2003) Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism. Atherosclerosis 169, 63-70